Peptide Therapy | DSIP, Subcutaneous

DSIP, Subcutaneous

Uses:

  • Treatment of pain
  • Alcohol and opioid withdrawal
  • Stress-related symptoms
  • Promotes sleep

Description

DSIP is a well-known neuromodulator and natural somnogenic nonapeptide with many other physiological functions. It is typically found in the brain and easily passes the blood-brain barrier. It is mainly prescribed for the treatment of pain conditions, alcohol, and opioid withdrawal, CRH and stress-related symptoms, low testosterone (via stimulation of LH), and even sometimes as an antioxidant and anti-oncogenic protein. It has been discovered and heavily studied for over 40 years, yet, the mechanism of action is still complex and not well understood. The results of studies of DSIP and its analogues over a period of 30 years since its discovery enable one to state with confidence that DSIP is a unique member of the family of peptide neuromodulators. It exhibits a pronounced stress-protective action and decreases stress-induced metabolic and functional disorders in human and animal organisms exposed to a variety of stresses. Some of the effects of the peptide are accomplished through the modulating action on central regulatory processes, owing to the systemic antioxidant action, the modulating influence on the activity of GABAergic, glutamatergic, and other neuronal systems. It also works on the expression of early response genes in brain structures, and on the activity of biosynthetic and proteolytic processes. DSIP has traditionally been dosed as an IV infusion, however, it can be given subcutaneously as well. Traditional doses have been 100mcg.

Clinical Research

DSIP: More than a sleep peptide?

In several species, DSIP at low doses has been shown to promote sleep. Although its physiological role remains to be clarified, DSIP illustrates several concepts applicable to other brain peptides. These include the bell-shaped dose-response curve, central effects after peripheral administration, a delayed and prolonged-time course, and some penetration of the blood-brain barrier in essentially intact form. Concepts applicable to one neuropeptide, therefore, appear to be applicable to others. In this article, Abba Kastin and colleagues review the known effects of DSIP and argue that more work needs to be carried out before it can be labeled functionally.

If you want further information about what DSIP is or about Peptide Therapy, a member of our Functional Medicine team can help you out by providing you with information about it.  Just fill out the form below.


Contact Us